高危非肌层浸润性膀胱癌重复经尿道切除术的系统综述
该研究系统检索了PubMed/Medline和Web of Science数据库,筛选出31篇文献共8409例高级别Ta和T1期膀胱癌患者,评估早期重复经尿道切除术(reTUR)的实践和治疗获益。结果显示初次TUR后残留肿瘤常见(Ta期17-67%,T1期20-71%),大多数残留位于原切除部位,reTUR有助于诊断残留癌并可能改善T1期患者的结局,但证据质量较弱。
要点
- 初次TUR后Ta期残留肿瘤17-67%,T1期20-71%,多数位于原切除部位
- reTUR后分期升级:Ta至≥T1为0-8%,T1至≥T2为0-32%
- reTUR对复发和癌症特异性死亡的影响数据矛盾
核心结论
- 高危NMIBC患者TUR后残留肿瘤常见,reTUR有助于诊断残留癌并可能改善初始分期为T1的癌症结局。
主要发现
- 初次TUR组织学检出逼尿肌的比例为30-100%。
- reTUR时Ta期残留肿瘤比例为17-67%,T1期为20-71%。
- 大多数残留肿瘤(36-86%)位于原切除部位。
- 分期升级:Ta至≥T1为0-8%,T1至≥T2为0-32%。
- 关于reTUR对后续复发和癌症特异性死亡率的影响,数据存在矛盾。
关键数值与推荐
- Ta期复发率:reTUR组16%,非reTUR组58%。
- T1期复发率范围为18-56%,但reTUR与对照组之间未发现明确趋势。
- Ta期未发现reTUR与进展之间的明确关系;T1期在设有对照人群的系列研究中,非reTUR组进展率更高(5/6项研究)。
- 两项设有对照的研究显示,reTUR组总死亡率略有降低(22-30% vs 26-36%[无reTUR])。
临床怎么用
- 对高危NMIBC(高级别Ta和T1期)考虑行早期reTUR以诊断残留肿瘤并可能改善T1期结局。
- reTUR可发现残留肿瘤和分期升级,应结合初次TUR病理(逼尿肌存在与否)和肿瘤分期决定是否行reTUR。
局限性
- reTUR对复发和癌症特异性死亡影响的证据存在矛盾。
- 关于reTUR获益的证据质量较弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Initial treatment for most bladder cancers (BCs) involves transurethral resection (TUR) or tumours. Often more cancer is found after the initial treatment in around half of patients, requiring a second resection. Repeat transurethral resection (reTUR) is recommended for high-risk, non-muscle-invasive bladder cancer (NMIBC) to remove any residual disease and improve cancer outcomes. OBJECTIVE: To systematically review the practice and therapeutic benefit of an early reTUR for high-risk NMIBC. EVIDENCE ACQUISITION: A systematic review of original articles was performed using PubMed/Medline and Web of Science databases in December 2016 (initial) and October 2017 (final). We searched the references of included papers. EVIDENCE SYNTHESIS: We screened 15 209 manuscripts and selected 31 detailing 8409 persons with high-grade Ta and T1BC for inclusion. Detrusor muscle was found at initial TUR histology in 30-100% of cases. Residual tumour at reTUR was found in 17-67% of patients following Ta and in 20-71% following T1 cancer. Most residual tumours (36-86%) were found at the original resection site. Upstaging occurred in 0-8% (Ta to ≥T1) and 0-32% (T1 to ≥T2) of cases. Conflicting data report the impact of reTUR on subsequent recurrence and cancer-specific mortality. Recurrence for Ta was 16% in the reTUR group versus 58% in the non-reTUR group. For T1, recurrence ranged from 18% to 56%, but no clear trend was identified between reTUR and control. No clear relationship between reTUR and progression was found for Ta, although for T1 rates were higher in the non-reTUR group in series with control populations (5/6 studies). Overall mortality was slightly reduced in the reTUR group in two studies with controls (22-30% vs 26-36% [no reTUR]). CONCLUSIONS: Residual tumour is common after TUR for high-risk NMIBC. The reTUR helps in the diagnosis of this residual cancer and may improve outcomes for cancers initially staged as T1. PATIENT SUMMARY: Some bladder cancers (BCs) are aggressive but confined to the bladder surface. Initial treatment includes endoscopic resection. More cancer is found after the initial treatment in approximately half of patients. In the aggressive but confined group of BC, a second resection, a few weeks after the first, may help find this residual cancer and improve outcomes, although the evidence quality for this is weak.
引用
- Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018. PMID: 29523366. doi:10.1016/j.eururo.2018.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。